Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELOS: Pembrolizumab with Induction Chemotherapy in Advanced Laryngeal/Hypopharyngeal Cancer
NCT06137378Phase 2Recruiting
- Sponsor
- Leipzig University
- Start
- Apr 2024
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in laryngeal squamous cell carcinoma (LSCC), hypopharyngeal squamous cell carcinoma (HSCC), sponsored by Leipzig University. Started Apr 2024; status: recruiting.
02
Drugs
03
Conditions
laryngeal squamous cell carcinoma (LSCC)hypopharyngeal squamous cell carcinoma (HSCC)
Beyond the preview
Go deeper on NCT06137378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06137378.